Compare Advance Auto Parts, Inc. (AAP) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.1 (market cap $3.19B), while Ginkgo Bioworks Holdings Inc trades at $7.4 (market cap $505.73M). The key difference: Advance Auto Parts, Inc. is far larger — about 6.3× Ginkgo Bioworks Holdings Inc's market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AAP | DNA | |
|---|---|---|
Market Cap | $3.19B | $505.73M |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $16.14 |
52-Week Low | $38.75 | $5.48 |
Enterprise Value | $5.47B | $607.68M |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.73, down 3.58% today, reflecting bearish technical signals amid mixed fundamentals. The company reported Q1 2026 EPS of $0.77, beating expectations, with revenue at $8.6 billion for 2025 but a slim net income margin of 0.51%. Recent news highlights restructuring efforts and AI-driven delivery initiatives to stabilize operations.
The outlook is cautious; while valuation ratios like P/S of 0.37 appear attractive, weak profitability and negative operating cash flow pose risks. Analyst consensus is mixed with a $61.30 price target, but high debt and competitive pressures require monitoring for sustained turnaround progress.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
